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ORIGINAL INVESTIGATION
The anti-inflammatory function 
of HDL is impaired in type 2 diabetes: role 
of hyperglycemia, paraoxonase-1 and low grade 
inflammation
Sanam Ebtehaj1, Eke G. Gruppen2, Mojtaba Parvizi3, Uwe J. F. Tietge1*† and Robin P. F. Dullaart2†
Abstract 
Background: Functional properties of high density lipoproteins (HDL) are increasingly recognized to play a physi-
ological role in atheroprotection. Type 2 diabetes mellitus (T2DM) is characterized by low HDL cholesterol, but the 
effect of chronic hyperglycemia on the anti-inflammatory capacity of HDL, a metric of HDL function, is unclear. There-
fore, the aim of the present study was to establish the impact of T2DM on the HDL anti-inflammatory capacity, taking 
paraoxonase-1 (PON-1) activity and low grade inflammation into account.
Methods: The HDL anti-inflammatory capacity, determined as the ability to suppress tumor necrosis factor-α (TNF-α) 
induced vascular cell adhesion molecule-1 (VCAM-1) mRNA expression in endothelial cells in vitro (higher values 
indicate lower anti-inflammatory capacity), PON-1 (arylesterase) activity, hs-C-reactive protein (hs-CRP), serum amyloid 
A (SAA) and TNF-α were compared in 40 subjects with T2DM (no insulin or statin treatment) and 36 non-diabetic 
subjects.
Results: T2DM was associated with impaired HDL anti-inflammatory capacity (3.18 vs 1.05 fold increase in VCAM-1 
mRNA expression; P < 0.001), coinciding with decreased HDL cholesterol (P = 0.001), apolipoprotein A-I (P = 0.038) 
and PON-1 activity (P = 0.023), as well as increased hs-CRP (P = 0.043) and TNF-α (P = 0.005). In all subjects combined, 
age- and sex-adjusted multivariable linear regression analysis demonstrated that impaired HDL anti-inflammatory 
capacity was associated with hyperglycemia (β = 0.499, P < 0.001), lower PON-1 activity (β = − 0.192, P = 0.030) and 
higher hs-CRP (β = 0.220, P = 0.016).
Conclusions: The HDL anti-inflammatory capacity is substantially impaired in T2DM, at least partly attributable to the 
degree of hyperglycemia, decreased PON-1 activity and enhanced low grade chronic inflammation. Decreased anti-
inflammatory protection capacity of HDL conceivably contributes to the increased atherosclerosis risk associated with 
T2DM.
Keywords: High sensitivity C-reactive protein, High density lipoprotein function, Paraoxonase-1, Serum amyloid A, 
Type 2 diabetes mellitus
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Introduction
Patients with type 2 diabetes mellitus (T2DM) have a sub-
stantially increased risk of atherosclerotic cardiovascular 
disease (CVD) [1]. This elevated CVD risk has been, at 
least in part, attributed to the low high density lipo-
protein (HDL) cholesterol levels consistently found in 
patients with insulin resistance and T2DM [2–4]. How-
ever, data from genetic as well as pharmacological inter-
vention studies now suggest that HDL cholesterol levels 
per se might not be as relevant as a predictive biomarker 
of atherosclerosis as previously thought [5–7]. Instead, 
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the functionality of HDL particles could have a more 
pathophysiologically important impact [8, 9], together 
with determinations of HDL subpopulations and HDL 
particle numbers [10–14]. HDL may slow the process of 
atherogenesis by several important biological proper-
ties. First, HDL promotes cholesterol efflux and reverse 
cholesterol transport, thereby removing cholesterol from 
macrophage foam cells in atherosclerotic lesions [8, 9]. 
Variable results have been reported on the impact of dia-
betes on HDL-mediated cholesterol efflux capacity, likely 
due to different assay conditions employed and reflect-
ing the influence of the severity of hyperglycemia [15–
17]. In a recent cross-sectional analysis of the CODAM 
study including 552 subjects we did not find evidence 
that moderate hyperglycemia as such impairs cholesterol 
efflux capacity [17]. Second, HDL can inhibit the oxida-
tion of native LDL thereby preventing the formation of 
pro-atherosclerotic and pro-inflammatory LDL particles 
[18]. Also for the effect of T2DM on the anti-oxidative 
capacity of HDL opposing data have been reported. 
In some studies, HDL from T2DM patients exhibited 
a reduced capacity to protect low density lipoproteins 
(LDL) from oxidation [19–21], whereas we found previ-
ously that the anti-oxidative capacity of HDL is impaired 
in T2DM but only taking account of the diabetes-asso-
ciated decrease in HDL cholesterol [22]. Again, these 
differences might be related to the degree of metabolic 
control in the T2DM patients studied. Third, HDL has 
potent anti-inflammatory activity and can reduce, e.g. 
endothelial activation [8, 9, 23], thus also interfering 
with an early step of atherogenesis. Notably, the anti-
inflammatory capacity of HDL was found to be impaired 
in acute myocardial infarction patients [24–26], and to 
predict recurrent CVD events even independent of HDL 
cholesterol and apolipoprotein (apo) A-I, the class-defin-
ing apolipoprotein of HDL [25]. Much less is currently 
known about the potential effect of T2DM specifically on 
the anti-inflammatory properties of HDL.
In the present cross-sectional study we tested the 
hypothesis that the anti-inflammatory function of HDL 
is impaired in T2DM. Furthermore, we aimed to deline-
ate the relationship of this metric of HDL function with 




The study protocol was approved by the medical eth-
ics committee of the University Medical Center Gron-
ingen. Men and women with and without T2DM, aged 
> 18 years, were recruited by advertisement in local news-
papers. They participated after written informed consent 
had been obtained. T2DM had been diagnosed previously 
according to guidelines from the Dutch College of Gen-
eral Practitioners (fasting plasma glucose ≥ 7.0 mmol/L; 
non-fasting plasma glucose ≥  11.1  mmol/L). Subjects 
with a history of CVD, chronic kidney disease (estimated 
glomerular filtration rate <  60  mL/min/1.73  m2 and/or 
proteinuria), liver function abnormalities or thyroid dys-
function, as well as current smokers and subjects who 
used lipid lowering drugs were also excluded. The use of 
metformin, sulfonylurea and antihypertensive medica-
tion was allowed, but insulin use was an exclusion crite-
rion. Blood pressure was measured after 15  min rest at 
the left arm in sitting position using a sphygmomanom-
eter. Body mass index (BMI in kg/m2) was calculated as 
weight divided by height squared. Waist circumference 
was measured between the 10th rib and the iliac crest. 
The metabolic syndrome (MetS) was defined according 
to the revised NCEP-ATP III criteria [27]. Three or more 
of the following criteria were required for categorization 
of subjects with MetS: waist circumference > 102 cm for 
men and > 88 cm for women, hypertension (blood pres-
sure ≥ 130/85 mmHg or use of antihypertensive medica-
tion), fasting plasma triglycerides ≥  1.70  mmol/L; HDL 
cholesterol < 1.0 mmol/L for men and < 1.3 mmol/L for 
women, fasting glucose ≥  5.6  mmol/L, or previously 
diagnosed T2DM. The participants were studied after an 
overnight fast.
Laboratory analyses
Serum and EDTA-anticoagulated plasma samples were 
stored at −  80  °C until analysis. Plasma glucose was 
measured shortly after blood collection with an APEC 
glucose analyzer (APEC Inc., Danvers, MA, USA).
Total cholesterol and triglycerides were measured by 
routine enzymatic methods (Roche/Hitachi Cat. Nos 
11875540 and 1187602, respectively; Roche Diagnos-
tics GmBH, Mannheim, Germany). HDL cholesterol 
was assayed by a homogeneous enzymatic colorimetric 
test (Roche/Hitachi, Cat. No 04713214). Non-HDL cho-
lesterol was calculated as the difference between total 
cholesterol and HDL cholesterol. LDL cholesterol was 
calculated by the Friedewald formula if triglycerides were 
< 4.5 mmol/L. Apolipoprotein A-I (apoA-I) and apolipo-
protein B (apoB) were measured by immunoturbidim-
etry (Roche/Cobas Integra Tinaquant Cat No. 03032566, 
Roche Diagnostics). Glycated hemoglobin (HbA1c) was 
measured by high-performance liquid chromatography 
(Bio-Rad, Veenendaal, the Netherlands; normal range: 
27–43 mmol/mol).
Serum paraoxonase-1 (PON-1) enzymatic activity was 
measured as arylesterase activity, i.e. as the rate of hydrol-
ysis of phenyl acetate into phenol [28, 29]. Arylesterase 
activity, measured with this assay, is positively correlated 
with PON-1 enzymatic activity toward paraoxon [30].
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High sensitivity C-reactive protein (hs-CRP) was 
assayed by nephelometry with a lower limit of 0.175 mg/L 
(BNII N; Dade Behring, Marburg, Germany). The serum 
amyloid A (SAA) protein was assayed by a monoclonal 
antibody-based sandwich SAA1 enzyme-linked immu-
nosorbent assay (ELISA) [31, 32]. Human apo-SAA was 
purified from the HDL3 fraction of acute phase serum, 
linked to helix pomatia haemocyanin, and subsequently 
injected into Balb/c mice to produce monoclonal antihu-
man-SAA antibodies. The antibodies used in the sand-
wich ELISA are the capture antibody Reu.86.5, which 
reacts to all acute phase SAA subtypes, and the coupled 
to Horseradish peroxidase detection antibody Reu.86.1, 
which reacts with the major SAA1 subtype. The assay is 
standardized against the international standard for SAA 
protein (WHO code 92/680). The lower limit of detec-
tion of the assay is 1.6  µg/L. Plasma TNF-α was meas-
ured using Luminex xMAP technology (Lincoplex panel 
B Cat. No. HADK1-61K-B; Linco Research Inc., St. 
Charles, MO, USA) [33]. TNF-α levels, measured with 
this technology, are strongly correlated (r  >  0.80) with 
assay results obtained by enzyme-linked immunoassays 
obtained from Linco Inc. (data provided by the manufac-
turer). The intra-assay coefficients of variation (CV) of all 
these assays are ≤ 8.0%.
The HDL anti-inflammatory capacity was deter-
mined using an in vitro cell system essentially following 
a recently described procedure [25, 26]. ApoB-contain-
ing lipoproteins were precipitated from plasma by add-
ing 100  μL 36% polyethylene glycol (PEG 6000, Sigma, 
St. Louis, MO, USA) in 10  mM HEPES (pH  =  8.0) to 
200  μL plasma followed by 30  min incubation on ice. 
After 30 min centrifugation at 2200g, the HDL-contain-
ing supernatant was collected, kept on ice, and used 
directly for the HDL anti-inflammatory assay. Human 
umbilical vein endothelial cells (HUVECs), pooled from 
at least 8 different donors, were provided by the Endothe-
lial Cell Core Facility of the University of Groningen, 
The Netherlands, and pre-incubated for 30  min with 
2% of individual apoB-depleted plasma samples or with 
equal amounts of phosphate buffered saline (PBS) as 
control [34]. Subsequently, 10  ng/mL TNF-α (R&D sys-
tems, Abingdon, UK) or PBS as control was added, and 
cells were incubated for an additional 5  h followed by 
analysis of vascular cell adhesion molecule-1 (VCAM-
1) gene expression using quantitative real-time poly-
merase chain reaction. VCAM-1 mRNA expression was 
calculated relative to the average of the housekeeping 
gene cyclophilin [34]. Results were further normalized 
to the average of the relative VCAM-1 expression of the 
control group. Individual values represent fold induc-
tion over control values, whereby higher values indi-
cate less suppression of VCAM-1 induction, i.e. lower 
anti-inflammatory capacity. In addition, under the assay 
conditions employed neither control HDL nor HDL from 
severely hyperglycemic patients affects the viability of the 
HUVECs (data not shown). Storage of plasma at − 80 °C 
did not influence the results of this assay [26]. The intra-
assay CV of this assay is 9% [26]. To limit potential vari-
ation due to different assay conditions, measurements of 
the anti-inflammatory function of HDL were carried out 
at the same time using the same batch of pooled cells and 
the same reagents.
Statistical analysis
IBM SPSS software (SPSS, version 22.0, SPSS Inc. Chi-
cago, IL, USA) was used for data analysis. Results are 
expressed as mean  ±  SD or as median (interquartile 
range). Because of skewed distribution, natural logarithm 
 (loge) transformed values of HDL anti-inflammatory 
capacity, triglycerides, hs-CRP, SAA and TNF-α were 
used. Between group differences in variables were deter-
mined by unpaired t tests or by Chi square tests. Univari-
ate correlations were determined by Pearson correlation 
coefficients. Multivariable linear regression analyses were 
carried out to disclose the independent relationships of 
HDL anti-inflammatory capacity with diabetes status, 
MetS classification, PON-1 activity and inflammation 
markers. Two-sided P < 0.05 were considered significant.
Results
Forty diabetic subjects (19 men/21 women) and 36 non-
diabetic subjects (8 men/28 women) were included in the 
study (Table 1). Twenty-eight T2DM subjects and 7 non-
diabetic subjects were classified with MetS (P  <  0.001). 
Among diabetic participants, diabetes duration was 5.0 
(4.0–6.7) years. All diabetic subjects had received diet 
advice as part of their routine medical care. Eight T2DM 
subjects were taking metformin alone and seven were 
taking sulfonylurea alone. Both drugs were used by 13 
T2DM participants. Other glucose lowering drugs were 
not taken. Twelve diabetic participants did not use glu-
cose lowering drugs. Anti-hypertensive medication 
(mainly angiotensin-converting enzyme inhibitors, angi-
otensin II receptor antagonists and diuretics, alone or in 
combination) were used by 18 T2DM subjects. None of 
the non-diabetic subjects used anti-hypertensive drugs 
(P  <  0.001). Three women were using estrogens. Other 
medications were not taken.
The T2DM subjects were older, and more likely to be 
men than the non-diabetic participants (Table  1). Sys-
tolic and diastolic blood pressure, BMI, waist circumfer-
ence, glucose and HbA1c levels were higher in T2DM 
subjects. Total cholesterol, non-HDL cholesterol, LDL 
cholesterol and apoB levels were not different between 
the groups. Triglyceride levels were higher, whereas 
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HDL cholesterol and apoA-I were lower in T2DM sub-
jects. The HDL anti-inflammatory capacity was strongly 
impaired in T2DM subjects [3.18 vs 1.05 fold increase 
in VCAM-1 mRNA expression (higher values indicate 
lower anti-inflammatory capacity); P  <  0.001, Table  1], 
coinciding with lower PON-1 activity, higher hsCRP 
and TNF-α levels. The difference in SAA between the 
groups was not significant. Additionally, the HDL anti-
inflammatory capacity was worse in all subjects with vs 
all subjects without MetS combined [3.16 (1.74–4.34) 
vs 1.24 (0.67–1.96) fold increase in VCAM1 expression, 
P  <  0.001]. The HDL anti-inflammatory capacity was 
also different in the diabetic subjects (n =  40) vs non-
diabetic subjects without MetS [n = 29; 1.03 (0.49–1.37) 
fold increase in VCAM1 expression, P < 0.001], but was 
not different between non-diabetic subjects with and 
without MetS (P =  0.11). Among diabetic subjects, the 
HDL anti-inflammatory capacity did not significantly 
differ between men and women [men 3.61 (2.23–4.39) 
and women 3.02 (2.09–4.18) fold increase in VCAM1 
expression; P  =  0.64]. In non-diabetic subjects, the 
HDL anti-inflammatory capacity was also not differ-
ent between men and women [men 0.88 (0.44–1.37) 
and women: 1.06 (0.63–1.38) fold increase in VCAM1 
expression; P = 0.64].
In all subjects combined, the HDL anti-inflammatory 
capacity values were strongly correlated with glucose and 
HbA1c (Table 1). HDL anti-inflammatory capacity values 
were also positively correlated with age, systolic blood 
pressure, waist circumference, triglycerides, hsCRP and 
TNF-α, whereas inverse correlations were observed with 
HDL cholesterol and PON-1 activity (Table 1). In T2DM 
subjects separately, the HDL anti-inflammatory capac-
ity was correlated with glucose (r  =  0.357, P  =  0.024), 
whereas in non-diabetic subjects the HDL anti-inflam-
matory capacity was correlated with hs-CRP (r = 0.373, 
P  =  0.025). Figure  1 shows the univariate relationships 
of the HDL anti-inflammatory capacity with glucose, 
PON-1 activity and hs-CRP in all subjects combined and 
in T2DM and non-diabetic subjects separately.
Table 1 Clinical characteristics, plasma (apo)lipoproteins, paraoxonase-1 activity, inflammation markers and anti-inflam-
matory capacity of high density lipoproteins in 40 patients with type 2 diabetes mellitus (T2DM) and in 36 non-diabetic 
subjects, and univariate correlation coefficients with the HDL anti-inflammatory capacity in all subjects combined
Data are mean ± SD or medians (interquartile range). BMI, body mass index; HbA1c, glycated hemoglobin; apo, apolipoprotein; HDL, high density lipoproteins; apo, 
apolipoprotein; hs-CRP, high sensitivity C-reactive protein; LDL, low density lipoproteins; PON-1, paraoxonase-1; SAA, serum amyloid A; TNF-α, tumor necrosis factor-α; 
VCAM-1, vascular cell adhesion molecule-1. LDL cholesterol was calculated in 38 T2DM subjects and in 35 non-diabetic subjects. Pearson correlation coefficients 
are shown with  loge transformed values of triglycerides, hs-CRP, SAA, TNF-α and HDL anti-inflammatory capacity (higher values indicate lower anti-inflammatory 










Age (years) 60 ± 10 52 ± 9 < 0.001 0.008 0.94
Sex (men/women) 19/21 8/28 0.039
Systolic blood pressure (mmHg) 145 ± 20 129 ± 20 0.001 0.253 0.028
Diastolic blood pressure (mmHg) 87 ± 9 81 ± 12 0.039 0.184 0.054
BMI (kg/m2) 28.9 ± 4.9 25.2 ± 4.1 0.001 0.302 0.008
Waist (cm) 99 ± 14 83 ± 13 0.375 0.001
Glucose (mmol/L) 8.8 ± 2.3 5.6 ± 0.7 < 0.001 0.614 < 0.001
HbA1c (mmol/mol) 50 ± 8 34 ± 3 < 0.001 0.432 < 0.001
Total cholesterol (mmol/L) 5.54 ± 0.97 5.58 ± 0.89 0.87 − 0.024 0.84
Non-HDL cholesterol (mmol/L) 4.24 ± 1.05 3.98 ± 1.00 0.27 0.072 0.54
LDL cholesterol (mmol/L) 3.41 ± 0.88 3.38 ± 0.88 0.91 − 0.024 0.84
HDL cholesterol (mmol/L) 1.30 ± 0.39 1.60 ± 0.35 0.001 − 0.242 0.035
Triglycerides (mmol/L) 1.67 (1.22–2.16) 1.15 (0.88–1.75) 0.004 0.258 0.025
ApoB (g/L) 0.97 ± 0.24 0.88 ± 0.22 0.095 0.120 0.30
ApoA-I (g/L) 1.36 ± 0.26 1.48 ± 0.20 0.038 − 0.140 0.22
PON-1 activity (U/L) 111.2 ± 38.1 131.2 ± 36.3 0.023 − 0.291 0.011
hs-CRP (mg/L) 1.58 (0.99–2.85) 0.94 (0.42–2.47) 0.043 0.253 0.029
SAA (mg/L) 1.71 (1.25–2.48) 1.58 (0.82–2.18) 0.25 0.211 0.067
TNF-α (ng/L) 3.50 (2.80–5.20) 2.95 (2.40–3.48) 0.005 0.240 0.038
HDL anti-inflammatory capacity (fold increase in 
VCAM-1 mRNA expression)
3.18 (2.17–4.33) 1.05 (0.63–1.38) < 0.001
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Multivariable linear regression analyses were first car-
ried out to determine whether the HDL anti-inflamma-
tory capacity remained associated with the presence 
of T2DM when taking account of age, sex, categoriza-
tion of MetS, and the use of glucose lowering drugs and 
anti-hypertensive medication. In age- and sex-adjusted 
analysis, the HDL anti-inflammatory capacity was associ-
ated with the presence of T2DM (β = 0.660, P < 0.001) 
independent of MetS categorization (β = 0.148, P = 0.10; 
data not shown). The association of the HDL anti-
inflammatory capacity with T2DM was unaltered after 
additional adjustment for glucose lowering medication 
and anti-hypertensive drugs (β  =  0.705, P  <  0.001); in 
this analysis the association of HDL anti-inflammatory 
capacity with MetS was again not significant (β = 0.155, 
P = 0.11). Given that the HDL anti-inflammatory capac-
ity was also correlated positively with systolic blood pres-
sure, waist circumference and plasma triglycerides, and 
inversely with HDL cholesterol in all subjects combined 
(Table  1), we performed further multivariable regres-
sion analysis with the HDL anti-inflammatory capacity 
as dependent variable and these individual MetS-related 
variables as potential contributing covariates. In such 
age- and sex-adjusted analyses, the HDL anti-inflamma-
tory capacity was again positively related to the presence 
of diabetes (β =  0.765, P  <  0.001) without independent 
contributions of systolic blood pressure (β  =  −  0.039, 
P = 0.63), waist circumference (β = − 0.019, P = 0.87), 
triglyceride levels (β = − 0.039, P = 0.63) and HDL cho-
lesterol (β = 0.080, P = 0.50).
We next evaluated the relationship of the HDL anti-
inflammatory capacity with glycemia, PON-1 activity and 
inflammation markers, representing variables with which 
the HDL anti-inflammatory capacity was correlated in 
univariate correlation analysis (Table 1). In age- and sex-
adjusted analysis the HDL anti-inflammatory capacity 
was associated positively with glucose and inversely with 
PON-1 activity (Table  2A); these relationships were not 
modified by HDL cholesterol or apoA-I (β  =  −  0.008; 
P  =  0.94 and β  =  −  0.019; P  =  0.85, respectively). Of 
the three inflammation markers, the strongest univari-
ate association with the HDL anti-inflammatory capacity 
was found for hs-CRP. In agreement, in age- and sex-
adjusted analyses the HDL anti-inflammatory capacity 
was associated with hs-CRP (β =  0.279, P =  0.025) but 
not independently with TNF-α (β  =  0.081, P  =  0.47) 
and SAA (β =  0.078, P =  0.52). hs-CRP was, therefore, 
chosen for further analysis. In a subsequent model, the 
HDL anti-inflammatory capacity was positively asso-
ciated with hs-CRP independent of plasma glucose 
(Table 2A, Model 2). When glucose, PON-1 activity and 
hs-CRP were included together in the analysis, the HDL 
anti-inflammatory capacity was still positively associ-
ated with glucose and hs-CRP and inversely with PON-1 
activity (Table  2A, Model 3). These relationships were 
essentially unaltered taking account of glucose lowering 
drugs and antihypertensive medication (data not shown). 
In alternative analyses with HbA1c instead of plasma 
Fig. 1 Scatterplots showing univariate relationships of high density 
lipoprotein (HDL) anti-inflammatory capacity (fold increase in 
VCAM-1 expression) in 40 subjects with type 2 diabetes mellitus 
(T2DM) (empty circles) and in 36 subjects without diabetes (filled 
circles) with plasma glucose (a), paraoxonase-1 (PON-1) activity (b) 
and high sensitivity C-reactive protein (hsCRP) (c). Higher HDL anti-
inflammatory capacity values represent lower HDL anti-inflammatory 
function. The HDL anti-inflammatory capacity and hsCRP values are 
 loge transformed. Correlation coefficients: a all subjects combined: 
r = 0.614, P < 0.001; T2DM subjects; r = 0.357, P = 0.024; non-diabetic 
subjects: r = − 0.127, P = 0.46. b All subjects combined: r = − 0.291, 
P = 0.011; T2DM subjects; r = 0.014, P = 0.93; non-diabetic subjects: 
r = − 0.315, P = 0.061. c All subjects combined: r = 0.253, P = 0.029; 
T2DM subjects; r = − 0.258, P = 0.11; non-diabetic subjects: 
r = 0.373, P = 0.025
Page 6 of 9Ebtehaj et al. Cardiovasc Diabetol  (2017) 16:132 
glucose, the HDL anti-inflammatory capacity was posi-
tively associated with HbA1c and inversely with PON-1 
activity (Table 2B, Model 1), positively with HbA1c and 
hs-CRP (Table 2B, Model 2), positively with HbA1c and 
hs-CRP, and inversely with PON-1 activity (Table  2B, 
Model 3). Combined, these results indicate that the HDL 
anti-inflammatory capacity is impaired in the context of 
chronic hyperglycemia, even independent of HDL cho-
lesterol, diabetes-associated impaired PON-1 activity and 
enhanced low grade chronic inflammation.
Discussion
The results of this study demonstrate that the anti-inflam-
matory properties of HDL are remarkably impaired in 
T2DM, even in patients with generally acceptable meta-
bolic control. It seems conceivable that such an impaired 
functionality of HDL may contribute to the increase in 
risk of atherosclerotic CVD associated with T2DM.
In this study, we used an assay that determines the 
effect of HDL preparations on the expression of VCAM-1 
on endothelial cells [25, 26]. Thereby, the read-out of 
HDL function is envisaged to directly reflect a criti-
cal early event in the process of atherogenesis, namely 
the recruitment of macrophages into developing ath-
erosclerotic lesions. In this respect, our study adds to 
previous work showing that HDL from T2DM patients 
exhibits decreased endothelial cell-dependent vasopro-
tective properties including reduced NO production, 
endothelium-dependent vasodilation and reendotheli-
alization after injury [35]. Another study using a differ-
ent type of assay also reached the conclusion that the 
diabetic state impacts negatively on the anti-inflamma-
tory function of HDL [21]. This report demonstrated 
impaired anti-inflammatory activity of HDL in T2DM 
determined as HDL-mediated inhibition of LDL-induced 
chemotaxis of macrophages towards endothelial cell-
conditioned medium. As a mechanism, the enrichment 
of HDL with SAA was suggested to explain decreased 
anti-inflammatory properties of HDL [21]; T2DM may 
result in increased circulating SAA levels already in 
young patients [36]. These data are also consistent with 
previous work in patients with end-stage renal disease 
[37], in which SAA was indeed identified as underlying 
factor for impaired HDL anti-inflammatory function. Lit-
erature points to a contribution of SAA, which is largely 
contained within the HDL fraction [38], to attenuated 
HDL function [8, 37]. However, in our present study we 
found no significant association of SAA with a decreased 
HDL anti-inflammatory function, although PON-1 activ-
ity is impaired by SAA [32]. The absence of an inde-
pendent association of the HDL anti-inflammatory 
function as observed here could have been due to the 
small number of participants. Rather, besides an antici-
pated effect of PON-1 activity [29, 39–41], an impaired 
HDL anti-inflammatory capacity was related indepen-
dently with plasma glucose levels as well as with glycated 
Table 2 Multivariable linear regression analysis showing associations of  the HDL anti-inflammatory capacity (deter-
mined as fold increase in VCAM-1 expression) with glucose, glycated hemoglobin, paraoxonase-1 activity and inflamma-
tion markers
A: Model 1: includes age, sex, glucose and PON-1 activity as independent variables. Model 2: includes age, sex, glucose and hs-CRP as independent variables. Model 3: 
includes age, sex, glucose, PON-1 activity and hs-CRP as independent variables
B: Model 1: includes age, sex, HbA1c and PON-1 activity as independent variables. Model 2: includes age, sex, HbA1c and hs-CRP as independent variables. Model 3: 
includes age, sex, HbA1c, PON-1 activity and hs-CRP as independent variables
β, standardized regression coefficient; PON-1, paraoxonase-1; HbA1c, glycated hemoglobin; hs-CRP, high sensitivity C-reactive protein; the HDL anti-inflammatory 
capacity and hs-CRP are  loge transformed. A positive association indicates a relationship with lower HDL anti-inflammatory capacity
Model 1 Model 2 Model 3
β P value β P value β P value
A
 Age − 0.118 0.23 0.155 0.120 0.168 0.084
 Sex (men/women) 0.046 0.61 0.103 0.26 0.086 0.335
 Glucose 0.535 < 0.001 0.521 < 0.001 0.499 < 0.001
 PON-1 activity − 0.240 0.009 − 0.192 0.030
 hs-CRP 0.232 0.013 0.220 0.016
B
 Age 0.197 0.059 0.241 0.028 0.253 0.018
 Sex (men/women) 0.049 0.63 0.112 0.28 0.093 0.36
 HbA1c 0.395 < 0.001 0.345 0.003 0.326 0.004
 PON-1 activity − 0.255 0.010 − 0.216 0.028
 hs-CRP 0.223 0.038 0.211 0.044
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hemoglobin, thereby probably pointing towards glycation 
as a potential mechanism. Previous work has established 
that glycation of apoA-I impairs the anti-inflammatory 
properties of HDL thereby lending experimental plausi-
bility to such a mechanism [42]. We observed an associa-
tion of impaired HDL anti-inflammatory function with 
hs-CRP as global marker of enhanced low-grade inflam-
mation. This relationship expands on previous findings 
about the impact of inflammation on HDL function [8, 
43], although for hs-CRP no direct mechanistic role in 
affecting HDL’s atheroprotective abilities has been estab-
lished, yet.
Several methodological considerations and potential 
limitations of our study need to be appreciated. First, we 
conducted a cross-sectional study in a relatively small 
number of participants. As a result, cause-effect rela-
tionships cannot be established with certainty. Second, 
the anti-inflammatory function of HDL was strongly 
impaired even in T2DM patients with generally accept-
able metabolic control. Remarkably, this metric of HDL 
function was not only associated with fasting plasma glu-
cose but also with the HbA1c level, supporting the notion 
that chronic hyperglycemic exposure may adversely 
impact on anti-inflammatory properties of HDL. In this 
vein, it seems plausible that more severe hyperglycemia 
could even have a greater impact. Third, we excluded 
subjects who used lipid lowering treatment. As a result, 
it is likely that diabetic subjects with mild lipoprotein 
abnormalities were preferentially included in our study. 
Accordingly, apoB-containing lipoprotein levels were 
not elevated in the presently included diabetic subjects. 
However, this might limit extrapolation of the cur-
rent findings to subjects with more severe dyslipidemia. 
Fourth, it would be interesting to assess determinants 
of HDL subpopulations and HDL particle numbers, 
measures of HDL that are linked to function and pro-
vide clinical information beyond HDL-C mass meas-
urements [10–14]. Lastly, it is important to note that 
the biological response of HUVECs is variable [44]. Our 
experimental approach takes this notion into account; 
all measurements were done on pooled HUVECs from 
different donors exactly at the same time with identical 
reagents. Still, these sorts of HDL function assays are not 
comparable to clinical chemistry determinations.
While we previously showed that impaired anti-inflam-
matory function of HDL predicts recurrent CVD events 
in myocardial infarction patients [25], prospective studies 
seem also warranted to explore the impact of this metric 
of HDL function on the future development of CVD in 
T2DM. Moreover, the robust independent association of 
the anti-inflammatory capacity of HDL with hyperglyce-
mia underscores the need to explore the effect of tight 
metabolic control on HDL function in future studies.
Conclusions
Our present results are consistent with the concept that 
T2DM relatively early in the course of the disease exerts a 
substantial negative impact on a critical atheroprotective 
function of HDL, namely protection against endothelial 
inflammation. Our data indicate that even mild hypergly-
cemia already significantly decreases this important met-
ric of HDL function.
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